Cargando…

Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial

IMPORTANCE: The morbidity and mortality associated with COVID-19 remain high despite advances in standard of care therapy, and the role of anti-inflammatory agents that inhibit the interleukin 6/JAK2 pathway is still being elucidated. OBJECTIVE: To evaluate the efficacy and safety of the oral JAK2/I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cafardi, John, Miller, Carole, Terebelo, Howard, Tewell, Chad, Benzaquen, Sadia, Park, David, Egan, Pamela, Lebovic, Daniel, Pettit, Kristen, Whitman, Eric, Tremblay, Douglas, Feld, Jonathan, Buckley, Sarah, Roman-Torres, Karisse, Smith, Jennifer, Craig, Adam, Mascarenhas, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855296/ https://www.ncbi.nlm.nih.gov/pubmed/36469321 http://dx.doi.org/10.1001/jamanetworkopen.2022.42918

Ejemplares similares

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
por: Bewersdorf, Jan, et al.
Publicado: (2023)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
por: Gagelmann, Nico, et al.
Publicado: (2023)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2023)

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis
por: Al-Fayoumi, Suliman, et al.
Publicado: (2018)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

Emerging treatment options for myelofibrosis: focus on pacritinib
por: Chow, Vivian, et al.
Publicado: (2016)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
por: Vannucchi, A., et al.
Publicado: (2022)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

Profile of pacritinib and its potential in the treatment of hematologic disorders
por: Hatzimichael, Eleftheria, et al.
Publicado: (2014)

P1059: COMPARATIVE EFFICACY OF FEDRATINIB AND PACRITINIB FOR THE TREATMENT OF MYELOFIBROSIS IN PATIENTS WITH LOW PLATELET COUNTS: A SIMULATED TREATMENT COMPARISON STUDY
por: Tremblay, G., et al.
Publicado: (2022)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice
por: Petrova, Tsvetana, et al.
Publicado: (2023)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
por: Torres, Sandra, et al.
Publicado: (2023)

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib
por: Yacoub, Abdulraheem, et al.
Publicado: (2023)

Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3
por: Ghezzi, Chiara, et al.
Publicado: (2023)

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
por: Hart, S, et al.
Publicado: (2011)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

Intravenous Immunoglobulin as Salvage Therapy in Refractory Pyoderma Gangrenosum: Report of a Case and Review of the Literature
por: Cafardi, John, et al.
Publicado: (2014)

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
por: Novotny-Diermayr, V, et al.
Publicado: (2012)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
por: Verstovsek, Srdan, et al.
Publicado: (2016)

Pacritinib Inhibition of IRAK1 Blocks Aberrant TLR8 Signalling by SARS-CoV-2 and HIV-1-Derived RNA
por: Campbell, Grant R., et al.
Publicado: (2022)

P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL
por: Zamora, Ernesto José Cuenca, et al.
Publicado: (2023)

Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature
por: Cafardi, John M., et al.
Publicado: (2015)

Considering direct-acting antivirals to cure hepatitis C virus during pregnancy: is this the last treatment frontier?
por: Kushner, Tatyana, et al.
Publicado: (2019)

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

Opportunistic Fungal Infection Associated With COVID-19
por: Cafardi, John, et al.
Publicado: (2021)

2511. Characterization of Patient Pill Preferences from a Prospective Placebo vs. Placebo Ease of Swallowability Study
por: Osborn, Zachary F, et al.
Publicado: (2019)

Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages
por: Chuang, Hao-Yu, et al.
Publicado: (2019)

Brucella Endocarditis in Persons Who Inject Drugs
por: Cafardi, John M, et al.
Publicado: (2020)

CNL and aCML are prognostically distinct: a large National Cancer Database analysis
por: Tremblay, Douglas, et al.
Publicado: (2023)

Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum
por: Ghose, Abhimanyu, et al.
Publicado: (2014)

Coinfection by Nocardia beijingensis and Nocardia arthritidis in an immunocompromised patient diagnosed by endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA)()
por: Aragaki-Nakahodo, Alejandro, et al.
Publicado: (2014)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Malignant pleural effusion from prostate adenocarcinoma
por: Knight, James C., et al.
Publicado: (2014)

Pneumonic‐type mucinous lung adenocarcinoma diagnosed by transbronchial cryobiopsy
por: Balestra, Rick, et al.
Publicado: (2017)

AN UNUSUAL PRESENTATION OF NONSPECIFIC INTERSTITIAL PNEUMONIA
por: Matta, Atul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4g2ckfq94mi2ud8ugc9b6l5jh7